These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10613749)

  • 21. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
    Wolters LM; Honkoop P; Niesters HG; de Man RA
    J Hepatol; 1998 May; 28(5):909-10. PubMed ID: 9625328
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.
    Hussain M; Lok AS
    J Viral Hepat; 1999 May; 6(3):183-94. PubMed ID: 10607230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with famciclovir against hepatitis B virus.
    Bartholomeusz A; Groenen LC; Locarnini SA
    Intervirology; 1997; 40(5-6):337-42. PubMed ID: 9675638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.
    Ono-Nita SK; Kato N; Shiratori Y; Carrilho FJ; Omata M
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2602-5. PubMed ID: 12121939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir.
    Shaw T; Mok SS; Locarnini SA
    Hepatology; 1996 Nov; 24(5):996-1002. PubMed ID: 8903366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo.
    Offensperger WB; Offensperger S; Keppler-Hafkemeyer A; Hafkemeyer P; Blum HE
    Antivir Ther; 1996 Aug; 1(3):141-6. PubMed ID: 11322247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
    Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
    Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Qi X; Xiong S; Yang H; Miller M; Delaney WE
    Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HBV gene variants and polymerse gene mutations in children with chronic hepatitis B in the course of the antiviral therapy].
    Góra-Gebka M; Liberek A; Charmuszko U; Sikorska-Wiśniewska G; Szlagatys-Sidorkiewicz A; Korzon M; Bielawski K
    Med Wieku Rozwoj; 2007; 11(4):367-71. PubMed ID: 18605187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
    Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.
    Bartholomeusz A; Tehan BG; Chalmers DK
    Antivir Ther; 2004 Apr; 9(2):149-60. PubMed ID: 15134177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
    Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
    J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.
    Lau GK; Tsiang M; Hou J; Yuen S; Carman WF; Zhang L; Gibbs CS; Lam S
    Hepatology; 2000 Aug; 32(2):394-9. PubMed ID: 10915748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
    Tipples GA; Ma MM; Fischer KP; Bain VG; Kneteman NM; Tyrrell DL
    Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.